今天给同学们分享一篇实验文章“CD8+ T cells maintain killing of MHC-I-negative tumor cells through the NKG2D-NKG2DL axis”,这篇文章发表在Nat Cancer期刊上,影响因子为22.7。 结果解读: MHC-I阴性肿瘤的免疫疗法需要CD8 T细胞 作者先前已经证明了4-1BB激动和抗程序性细胞死亡蛋白1(PD-1)检查点阻断(αPD...
今天给同学们分享一篇实验文章“CD8+ T cells maintain killing ofMHC-I-negative tumor cells through theNKG2D-NKG2DL axis”,这篇文章发表在Nat Cancer期刊上,影响因子为22.7。 结果解读: MHC-I阴性肿瘤的免疫疗法需要CD8 T细胞 作者先前已经证明了4-1BB激动和抗程序性细胞死亡蛋白1(PD-1)检查点阻断(αPD-1...
今天给同学们分享一篇实验文章“CD8+ T cells maintain killing of MHC-I-negative tumor cells through the NKG2D-NKG2DL axis”,这篇文章发表在Nat Cancer期刊上,影响因子为22.7。 结果解读: MHC-I阴性肿瘤的免疫疗法需要CD8 T细胞 作者先前已经证明了4-1BB激动和抗程序性细胞死亡蛋白1(PD-1)检查点阻断(αPD...
NKG2DL的表达在特定肿瘤或感染细胞中存在显着差异，也就是说，不同的刺激或病理状态可能引起不同NKG2DL的表达。陆续研究表明，ULBP1在多种类型的肿瘤细胞，包括白血病、淋巴瘤、黑色素瘤、乳腺癌、肺癌和胃癌等表达上调 [11-13]。ULBP1与NK细胞和T细胞上的NKG2D的相互作用可以激活它们对肿瘤细胞的细胞毒性活动。在...
NKG2D配体(NKG2D Ligands,NKG2DL)在广泛的血液恶性肿瘤中过表达。据CYAD-01的I期临床数据显示,通过CAR T细胞疗法靶向NKG2D配体可提高对这些肿瘤的治疗效果。ULBP1,作为NKG2D配体成员之一,在多种血液和实体肿瘤中高表达,使用NKG2D CAR-T靶向方法,有望增强对高表达ULBP1的肿瘤细胞的抗肿瘤活性。今天,我们一起探究ULBP1...
NKG2DL is polymorphic in MM cells. The decreased expression of NKG2DL on the cell surface is explained by multiple mechanisms of tumour immune escape. In this review, we discuss the mechanisms by which the NKG2D/NKG2DL axis regulates immune effector cells and strategies for promoting NKG2DL ...
In addition, we will highlight pathophysiological conditions associated with NKG2D/NKG2DL dysregulation and discuss the putative involvement of the NKG2D/NKG2DL axis in the lymphocyte/myeloid cell crosstalk in these diseases. 展开 关键词: NKG2D NKG2D ligands myeloid cells natural killer cells NKG2D+ T...
axis is a legitimate target for novel therapeutic approaches. One example is a recent finding of the “desensitization” mechanism which employs soluble high-affinity NKG2D ligands to restore NKG2D activity and tumor control. In addition to effector functions, analyses of NKG2D-deficient mouse models ...
2. Stojanovic, A., Correia, M. P., & Cerwenka, A. (2018). The NKG2D/NKG2DL Axis in the Crosstalk Between Lymphoid and Myeloid Cells in Health and Disease. Frontiers in immunology, 9, 827.https://doi.org/10.3389/fimmu.2018.00827 ...
2. Stojanovic, A., Correia, M. P., & Cerwenka, A. (2018). The NKG2D/NKG2DL Axis in the Crosstalk Between Lymphoid and Myeloid Cells in Health and Disease. Frontiers in immunology, 9, 827.https://doi.org/10.3389/fimmu.2018.00827 ...